Solana Company (HSDT) Q2 2024 Earnings Report

Solana Company (HSDT) reported Q2 2024 revenue of $182 thousand, a year-over-year decline of 28.9% and a sequential increase of 34.8% from Q1 2024. Despite a substantial top-line shortfall, the company continued to advance its reimbursement and market access strategy, highlighted by CMS HCPCS coding for PoNS controller and mouthpiece and the potential Medicare payment determinations effective October 1, 2024. Management emphasized progress with the VA network and third-party payers, including a May placement on Lovell’s VA federal schedules and a July DAPA contract, which collectively expand addressable reimbursement. The company also advanced registrational activities for stroke and risk-of-fall programs, positioning PoNS for FDA submission in 2025. Liquidity was strengthened by a May 2024 public offering that raised net proceeds of $5.5 million, extending runway into 2025, while maintaining a cash balance of approximately $6.4 million and no debt. Net loss for the quarter was $1.6 million, with an EPS of -0.64, reflecting ongoing R&D investments and limited scale. In the near term, management argues that Medicare reimbursement and VA market access are pivotal catalysts that could shift revenue growth and drive toward positive cash flow, contingent on CMS final rates and payer adoption. The investment thesis hinges on reimbursement momentum, data from stroke registrational activities, and the successful execution of the 2024-2025 milestones described on the earnings call and in the 10-Q filing.